Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain the NCT# and Site #.


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Back

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Recruiting

Open to: ALL

Age: 18.0 - N/A

Birmingham Surrey Edinburgh Kent Leicester London London Manchester

Medical Conditions

Lung Neoplasms
Carcinoma, Non-Small-Cell Lung

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.

The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2020 Oct 2028

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)

Intervention Arm Group : Phase 2 Cohort 1a: PD-L1 TPS <1%;

Intervention Type : DRUG
Intervention Description : Adagrasib 600 mg BID monotherapy (Cohort 1b)

Intervention Arm Group : Phase 2 Cohort 1b: PD-L1 TPS <1%;

Intervention Type : DRUG
Intervention Description : adagrasib 400 mg BID in combination with pembrolizumab

Intervention Arm Group : Phase 2 Cohort 2: PD-L1 TPS ≥1%;

Intervention Type : DRUG
Intervention Description : Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W

Intervention Arm Group : Phase 3 Cohort 3 Investigational Arm;

Intervention Type : DRUG
Intervention Description : Pembrolizumab 200 mg IV Q3W

Intervention Arm Group : Phase 3 Cohort 4 Comparator Arm;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham
    B9 5SS
  • Royal Surrey County Hospital NHS Foundation Trust
    Surrey
    GU2 7XX
  • Local Institution - 007-415
    Edinburgh
    EH4 2XU
  • Local Institution - 007-403
    Kent
    ME16 9QQ
  • University Hospitals of Leicester NHS Trust
    Leicester
    LE1 5WW
  • University College London Hospitals NHS Foundation Trust
    London
    NW1 2BU
  • Guys and St Thomas NHS Foundation Trust
    London
    SE1 9RT
  • The Christie NHS Foundation Trust
    Manchester
    M20 4BX

First line of the email MUST contain the NCT# and Site #.


BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com



The study is sponsored by Mirati Therapeutics Inc.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04613596
Last updated 16 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top